Latest APMD news

Apnimed: What We Know Heading Into The Feb PDUFA

Seeking Alpha · Thu, 10 Sep 2026 08:40:14 -0400

Apnimed, Inc. (APMD) is a late-stage, de-risked regulatory play with a fully funded path to commercialisation, focused on AD109 for obstructive sleep apnea (OSA). AD109 (Oxnimbi) demonstrated robust Phase 3 efficacy, clear differentiation from CPAP, and manageable safety, with an NDA under FDA review and a February 2027 PDUFA date. APMD's financials show a transition from R&D to pre-commercial buildout, with a strong cash position and multiple years of runway to support launch activities.

Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · Tue, 08 Sep 2026 16:39:00 -0400

CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update.

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · Fri, 04 Sep 2026 16:01:00 -0400

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on August 31, 2026, the compensation committee of Apnimed's board of directors granted 10 new non-executive employees non-qualified stock options to purchase an aggregate of 428,428 shares of the Company's common stock under Apnimed's 2026 Inducement Plan (the “Plan”). Each stock option granted has an exercise price per share of $26.85, which is equal to Apnimed's closing trading price on September 1, 2026. One-fourth of the shares underlying each of the employee's stock options will vest on the first anniversary of each employee's start date and in equal monthly installments thereafter for the next three years, subject to such employee's continued employment with the Company on such vesting dates.

Apnimed shares surge on bullish BofA initiation

Proactive Investors · Tue, 25 Aug 2026 12:22:40 -0400

Shares of Apnimed rose 8% Tuesday after BofA Securities initiated coverage of the company with a Buy rating and a $41 price target. The rating is based on a risk-adjusted discounted cash flow analysis of Oxnimbi (AD109), Apnimed's sole asset and an oral therapy for obstructive sleep apnea (OSA).

Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks

24/7 Wall Street · Fri, 14 Aug 2026 09:45:28 -0400

The Nasdaq debut of Apnimed (NASDAQ:APMD) has given public investors their first pure-play bet on a pill for obstructive sleep apnea (OSA).

Primary Markets Group July 2026 U.S. IPO Update

Seeking Alpha · Sat, 08 Aug 2026 10:30:00 -0400

The U.S. IPO market cooled in July following the record-shattering June. The month saw seven new issuers raise $3.0 billion in proceeds, a significant slowdown from the 19 deals and $97.9 billion priced in June that was skewed by the unprecedented SpaceX IPO. Looking at the six-month IPO backlog, 10 new issuers filed in July, bringing the total pipeline to 75 companies seeking to raise $3.2 billion in aggregate proceeds.

Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewsWire · Mon, 03 Aug 2026 16:35:00 -0400

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the closing of its upsized initial public offering of an aggregate of 13,800,000 shares of its common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,800,000 additional shares, at an initial public offering price of $16.00 per share.

Market information is provided for research and visualization and is not investment advice.